Dali Pharmaceuticalco.,Ltd

Shanghai Stock Exchange 603963.SS

Dali Pharmaceuticalco.,Ltd Revenue Per Share for the year ending December 31, 2023: USD 0.06

Dali Pharmaceuticalco.,Ltd Revenue Per Share is USD 0.06 for the year ending December 31, 2023, a -36.73% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Dali Pharmaceuticalco.,Ltd Revenue Per Share for the year ending December 31, 2022 was USD 0.09, a -28.94% change year over year.
Dali Pharmaceuticalco.,Ltd Revenue Per Share for the year ending December 31, 2021 was USD 0.12, a -17.52% change year over year.
Dali Pharmaceuticalco.,Ltd Revenue Per Share for the year ending December 31, 2020 was USD 0.15, a -22.58% change year over year.
Dali Pharmaceuticalco.,Ltd Revenue Per Share for the year ending December 31, 2019 was USD 0.19, a -23.67% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Shanghai Stock Exchange: 603963.SS

Dali Pharmaceuticalco.,Ltd

CEO	Mr. Jun Xiang Yang
IPO Date	Sept. 22, 2017
Location	China
Headquarters	No. 118, West Huancheng Road
Employees	272
Sector	Health Care
Industries Pharmaceuticals

Description

Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.

Key trends

Past 5 years